Sentry Investment Management LLC lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 1.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 139,032 shares of the healthcare product maker’s stock after purchasing an additional 1,448 shares during the period. Sentry Investment Management LLC’s holdings in Abbott Laboratories were worth $6,758,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Heritage Trust Co lifted its position in Abbott Laboratories by 10.1% in the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after acquiring an additional 200 shares during the last quarter. Winfield Associates Inc. lifted its position in Abbott Laboratories by 3.9% in the second quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after acquiring an additional 89 shares during the last quarter. Thompson Davis & CO. Inc. lifted its position in Abbott Laboratories by 17.7% in the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after acquiring an additional 370 shares during the last quarter. JFS Wealth Advisors LLC lifted its position in Abbott Laboratories by 349.0% in the second quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock valued at $131,000 after acquiring an additional 2,094 shares during the last quarter. Finally, Motco lifted its position in Abbott Laboratories by 213.7% in the second quarter. Motco now owns 2,880 shares of the healthcare product maker’s stock valued at $140,000 after acquiring an additional 1,962 shares during the last quarter. 71.32% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories (ABT) opened at $54.73 on Friday. Abbott Laboratories has a one year low of $37.90 and a one year high of $56.69. The company has a current ratio of 2.69, a quick ratio of 2.26 and a debt-to-equity ratio of 0.72. The stock has a market cap of $95,837.49, a PE ratio of 22.85, a PEG ratio of 2.06 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The business had revenue of $6.83 billion for the quarter, compared to analyst estimates of $6.72 billion. During the same period in the previous year, the business posted $0.59 earnings per share. The business’s revenue was up 28.8% compared to the same quarter last year. research analysts predict that Abbott Laboratories will post 2.49 EPS for the current year.

In other news, insider Jaime Contreras sold 52,700 shares of the business’s stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $51.97, for a total transaction of $2,738,819.00. Following the transaction, the insider now directly owns 58,739 shares in the company, valued at $3,052,665.83. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Sharon J. Bracken sold 2,188 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $56.12, for a total transaction of $122,790.56. Following the transaction, the insider now owns 25,618 shares in the company, valued at $1,437,682.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 616,332 shares of company stock worth $33,579,226. Company insiders own 0.76% of the company’s stock.

ABT has been the subject of a number of research reports. Cowen reissued a “buy” rating and issued a $55.00 price target on shares of Abbott Laboratories in a research report on Thursday, August 17th. Citigroup initiated coverage on shares of Abbott Laboratories in a research report on Thursday, August 17th. They issued a “neutral” rating and a $53.00 price target for the company. BMO Capital Markets reissued a “hold” rating and issued a $53.00 price target on shares of Abbott Laboratories in a research report on Friday, September 1st. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research report on Friday, September 22nd. Finally, Wells Fargo & Company boosted their price target on shares of Abbott Laboratories from $57.00 to $64.00 and gave the company an “outperform” rating in a research report on Thursday, September 28th. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $57.56.

COPYRIGHT VIOLATION NOTICE: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/12/15/abbott-laboratories-abt-stake-raised-by-sentry-investment-management-llc.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Stock Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related stocks with our FREE daily email newsletter.